Show simple item record

dc.contributor.authorCatalán Alcántara, Ana ORCID
dc.contributor.authorSalazar de Pablo, Gonzalo ORCID
dc.contributor.authorVaquerizo Serrano, Julio
dc.contributor.authorMosillo, Pierluca
dc.contributor.authorBaldwin, Helen
dc.contributor.authorFernández Rivas, Aranzazu
dc.contributor.authorMoreno, Carmen
dc.contributor.authorArango, Celso
dc.contributor.authorCorrell, Christoph U.
dc.contributor.authorBonoldi, Ilaria
dc.contributor.authorFusar-Poli, Paolo
dc.date.accessioned2021-06-21T08:20:48Z
dc.date.available2021-06-21T08:20:48Z
dc.date.issued2021-05
dc.identifier.citationJournal Of Child Psychology And Psychiatry 62(5) : 657-673 (2021)es_ES
dc.identifier.issn0021-9630
dc.identifier.issn1469-7610
dc.identifier.urihttp://hdl.handle.net/10810/51952
dc.description.abstractBackground The clinical high-risk state for psychosis (CHR-P) paradigm has facilitated the implementation of psychosis prevention into clinical practice; however, advancements in adolescent CHR-P populations are less established. Methods We performed a PRISMA/MOOSE-compliant systematic review of the Web of Science database, from inception until 7 October 2019, to identify original studies conducted in CHR-P children and adolescents (mean age <18 years). Findings were systematically appraised around core themes: detection, prognosis and intervention. We performed meta-analyses (employingQstatistics andI(2)test) regarding the proportion of CHR-P subgroups, the prevalence of baseline comorbid mental disorders, the risk of psychosis onset and the type of interventions received at baseline. Quality assessment and publication bias were also analysed. Results Eighty-seven articles were included (n = 4,667 CHR-P individuals). Quality of studies ranged from 3.5 to 8 (median 5.5) on a modified Newcastle-Ottawa scale.Detection: Individuals were aged 15.6 +/- 1.2 years (51.5% males), mostly (83%) presenting with attenuated positive psychotic symptoms. CHR-P psychometric accuracy improved when caregivers served as additional informants. Comorbid mood (46.4%) and anxiety (31.4%) disorders were highly prevalent. Functioning and cognition were impaired. Neurobiological studies were inconclusive.Prognosis: Risk for psychosis was 10.4% (95%CI: 5.8%-18.1%) at 6 months, 20% (95%CI: 15%-26%) at 12 months, 23% (95%CI: 18%-29%) at 24 months and 23.3% (95%CI: 17.3%-30.7%) at >= 36 months.Interventions: There was not enough evidence to recommend one specific treatment (including cognitive behavioural therapy) over the others (including control conditions) to prevent the transition to psychosis in this population. Randomised controlled trials suggested that family interventions, cognitive remediation and fish oil supplementation may improve cognition, symptoms and functioning. At baseline, 30% of CHR-P adolescents were prescribed antipsychotics and 60% received psychotherapy. Conclusions It is possible to detect and formulate a group-level prognosis in adolescents at risk for psychosis. Future interventional research is required.es_ES
dc.description.sponsorshipG.S.d.P. and J.V.S. are supported by the Alicia Koplowitz Foundation. The study has been supported by the Spanish Ministry of Science, Innovation, and Universities, Instituto de Salud Carlos III, European Regional Development Fund 'A way of making Europe,' Centro de Investigacion Biomedica en Red Salud Mental, Madrid Regional Government; and Fundacion Mutua Madrilena. A.C. has received personal fees from Janssen and grant support from the Instituto de Salud Carlos III, Spanish Ministry of Economy and Competitiveness. C.A. has been a consultant to or has received honoraria or grants from Acadia, Angelini, Gedeon Richter, Janssen Cilag, Lundbeck, Otsuka, Roche, Sage, Servier, Shire, Schering Plough, Sumitomo Dainippon Pharma, Sunovion and Takeda. C.M. has acted as consultant or participated in DMC for Janssen, Servier, Lundbeck, Nuvelution, Angelini and Otsuka and has received grant support from European Union Funds and Instituto de Salud Carlos III, Spanish Ministry of Economy and Competitiviness. C.U.C. has been a consultant and/or adviser to or has received honoraria from: Alkermes, Allergan, Angelini, Boehringer-Ingelheim, Gedeon Richter, Gerson Lehrman Group, Indivior, IntraCellular Therapies, Janssen/J&J, LB Pharma, Lundbeck, MedAvante-ProPhase, Medscape, Merck, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Servier, Sumitomo Dainippon, Sunovion, Supernus, Takeda and Teva. He has provided expert testimony for Bristol-Myers Squibb, Janssen and Otsuka. He served on a Data Safety Monitoring Board for Boehringer-Ingelheim, Lundbeck, Rovi, Supernus, and Teva. He received royalties from UpToDate and grant support from Janssen and Takeda. He is also a shareholder of LB Pharma. P.F-P. has been a consultant to and received research funds from Lundbeck and received honoraria from Menarini and Angelinies_ES
dc.language.isoenges_ES
dc.publisherWileyes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectpsychosises_ES
dc.subjectschizophreniaes_ES
dc.subjectclinical high-risk state for psychosises_ES
dc.subjectpsychosis riskes_ES
dc.subjectpreventiones_ES
dc.subjectevidencees_ES
dc.subjectpredictiones_ES
dc.subjectfirst-episodees_ES
dc.subjectmeta-analysises_ES
dc.subjectchildhoodes_ES
dc.subjectadolescencees_ES
dc.subjectclinical high-riskes_ES
dc.subjectultra-high-riskes_ES
dc.subjectreduced prepulse inhibitiones_ES
dc.subjectrandomized controlled-triales_ES
dc.subjectbehavior assessment systemes_ES
dc.subjecthelp-seeking adolescentses_ES
dc.subjectperceived social stresses_ES
dc.subjectquality-of-lifees_ES
dc.subjectyoung-peoplees_ES
dc.subjectindicated preventiones_ES
dc.titleAnnual Research Review: Prevention of Psychosis in Adolescents - Systematic Review and Meta-Analysis of Advances in Detection, Prognosis and Interventiones_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.holderThis is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0)es_ES
dc.rights.holderAtribución 3.0 España*
dc.relation.publisherversionhttps://acamh.onlinelibrary.wiley.com/doi/10.1111/jcpp.13322es_ES
dc.identifier.doi10.1111/jcpp.13322
dc.departamentoesNeurocienciases_ES
dc.departamentoeuNeurozientziakes_ES


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0)
Except where otherwise noted, this item's license is described as This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0)